Apolipeptides TRIZ Cases

Targeting oxidized LDL with an ApoB100-binding antibody reduces psoriasis severity while lowering atherosclerosis risk.

AAV delivery of protective APOE variants suppresses APOE4 activity and reduces amyloid and tau burden in Alzheimer's disease.

Copper, manganese, pH 7.0, and a temperature shift tune afucosylation and galactosylation without harming cell growth or productivity.

Artificial adiposomes mimic lipid droplets without organelle contamination, enabling cleaner in vitro composition studies and drug carrier design.

Apolipoprotein fused with a targeting protein improves lipid carrier binding and receptor-specific drug delivery while reducing off-target side effects.

Multispecific antibodies raise ApoL1 complex uptake into cancer cells, driving cell death as an alternative to resistant myeloma therapies.

rAAV delivery of Cas13 and multi-gRNA cassettes silences liver targets such as PCSK9 to lower cholesterol in statin-resistant patients.

Hybrid nanodiscs combine apolipoprotein, lipids, and telodendrimers to reduce aggregation while improving solubility and membrane protein stability.

Delta6PV targets T cell expansion to protect beta-cells, delay Type 1 Diabetes onset, and improve insulin production and glycemic control.

Modular Th and B-cell epitope peptides balance immunogenicity, uniform antibody induction, and low-cost synthesis for immunotherapeutics.

An Fc-fused MSP nanodisc boosts production yield and half-life while improving antiviral efficacy against mutation-prone viruses.

A tagged apolipoprotein interface lets one liponanoparticle platform bind different targeting molecules without redesigning the nanoparticle.

A soluble PAL variant lacking its membrane anchor boosts recombinant protein release during fermentation while preserving bacterial viability.

Short linked B-cell and Th epitope peptides improve antibody uniformity while keeping immunotherapeutic synthesis simpler and lower cost.

Anti-oxidized LDL antibodies paired with DMARDs target RA inflammation and atherosclerosis progression in one composite therapy.

APOE and glycerophospholipids form tunable carriers that cross the blood-brain barrier for targeted therapeutic payload delivery.

Novel ApoB100 peptides target HLA-presented T-cell responses to address inflammatory foam-cell formation and atherosclerotic plaque development.

By mimicking nascent discoidal pre-beta HDL, CER-001 promotes cholesterol efflux and reduces glomerular lipid droplets in kidney disease.

Low APOH expression is linked to hepatic steatosis and inflammation; targeted therapy restores lipid metabolism in fatty liver disease.

Controlled hydration and composition ranges produce uniform, high-purity lipoprotein complexes while limiting protein degradation.

This case uses ependyma-specific promoters and modified AAV capsids to target brain delivery and limit off-tissue expression.

PKM, ALDOA, LDHB, and apoE4 expression levels help distinguish Alzheimer’s disease from other dementias and guide treatment.

This case uses nanoscale assemblies to induce trained immunity, aiming to improve cancer treatment while reducing toxicity and resistance.

Unstable lipid standards hinder modified HDL testing; a recombinant ApoA I–LOX-1 fusion protein enables repeatable measurement.

A cell-free hybrid nanodisc method combines apolipoprotein, telodendrimer, and lipid to improve stability, solubility, and drug targeting.

Apo-I, sphingomyelin, and DPPG form phased-dose CER-001 to improve lipid profiles and slow kidney dysfunction.

Polymerizable lipids form cross-linked bilayers that resist disintegration and support active-molecule delivery in blood serum.

Adjusting pH and alcohol concentration precipitates apolipoprotein A-I while retaining alpha-1-antitrypsin in solution to prevent protein loss.

Specific proteins like LYZ2 mediate host environment interactions to resolve low survival rates and poor differentiation of transplanted neural cells.

Nested circularization domains constrain nanodisc dimensions to resolve size heterogeneity, enabling stable membrane protein analysis.

A dual transgenic mouse model expresses human apo(a) and apo B-100 genes to produce human lipoprotein(a) particles.

Ultracentrifugation separates IDL and VLDL subclasses to quantify cholesterol concentrations for cardiovascular risk assessment.

Guide RNA directs Cas9 nucleases to specific APOCIII targets, eliminating random insertion effects and improving treatment safety.

Short ApoA-I mimic peptides replicate functional properties of full-length proteins, reducing production costs while maintaining therapeutic efficacy.

Blood-based APOA2 isoform ratio measurement replaces invasive tube tests, improving diagnostic accuracy while reducing equipment complexity.

Segmented antibody therapy targeting ApoB100 and CD40L reduces cardiovascular complications while minimizing side effects from non-specific immunosuppression.

Replacing invasive liver biopsy with blood tests for dioxidized W72 peptides resolves the trade-off between diagnostic accuracy and patient discomfort.

Engineered porphobilinogen deaminase variants with specific amino acid mutations enhance catalytic activity and liver targeting.

Synthetic peptides derived from beta-2-glycoprotein-1 react with autoantibodies to enable rapid diagnostic testing.

Algae express milk proteins with correct folding and glycosylation, eliminating purification needs.

ApoA1 mimetic peptides substitute tryptophan residues with oxidant-resistant amino acids to promote cholesterol efflux from lipid-loaded cells.

A PEGylated Domain I beta2GPI conjugate binds anti-beta2GPI antibodies via cysteine residues to block pathogenic interactions.

Serum protein biomarkers quantify NAFLD severity without biopsy, resolving the trade-off between diagnostic accuracy and patient discomfort.

Synthetic ApoE-mimetic peptides lower atherosclerotic lesion size by accelerating cholesterol removal, eliminating the need for lifelong statin therapy.

Bacterial production of non-glycosylated apolipoprotein A-IV lowers blood glucose levels and addresses insulin resistance in type 2 diabetes.

Cell-free co-expression of scaffold proteins and lipids stabilizes membrane proteins, preventing aggregation during purification.

Recombinant apolipoprotein M restores normal serum and urine levels to protect kidney structure.

Universal Beta2GPI peptides capture multiple microorganism types simultaneously, eliminating complex multi-method workflows.

Inserting specific apolipoprotein(a) epitopes into chimeric HBcAg induces neutralizing antibodies without triggering autoimmune reactions.

Heat treatment prevents protein aggregation during filtration, enabling high log reduction values for small viruses.

Apolipoprotein A-IV peptide restores glucose tolerance by enhancing insulin secretion response to glucose stimuli.